Micreos Secures €12 Million for New Products Containing Staphefekt

Micreos has secured €12 million in additional equity for the global development of its antibacterial lysin technology, Staphefekt in new products. Micreos intends to use the secured funds, which run until 2017, for the global development of Staphefekt™ as a pharmaceutical (Rx) product.
According to the press release:

Micreos develops targeted antibacterial technology as a sustainable alternative to antibiotics for which it is a recognised leader in the field.
Gladskin is the world’s first lysin (enzyme) based product registered for human use. It specifically targets S. aureus, including MRSA on intact skin.

CEO Mark Offerhaus commented:

We are delighted with this influx of additional funding. It confirms investors’ continued confidence in our technology. Similar support can be found in the very favorable patient feedback in our OTC channel. In addition, there is an understanding that patient needs in many skin conditions are currently not being met. Clinical development is costly and time-consuming, but the millions of people who suffer from S. aureus related infections such as eczema, stand to benefit from the advancement brought about by this funding.

Click here to view the full press release.